Floatz logo

rg4733

Rectal Mucinous Adenocarcinoma

National Cancer Institute (NCI)Phase 1Dormant
C
35/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
20/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Rectal Mucinous Adenocarcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
University of Southern California
Phase 3BBB
Irinotecan
Fox Chase Cancer Center
Phase 3BBB
Eloxatin
Virginia Commonwealth University
Phase 3BBB
Irinotecan
National Cancer Institute (NCI)
Phase 3BB
Aflibercept
John Hays
Phase 2B

View all 20 →

Same molecule, other indications

rg4733 is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
melanomaDormant
CCC
Indicative ·
51 / 100
View asset →
Stage IV Skin MelanomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →